PE20010349A1 - Derivados de triazol e imidazol - Google Patents

Derivados de triazol e imidazol

Info

Publication number
PE20010349A1
PE20010349A1 PE2000000707A PE0007072000A PE20010349A1 PE 20010349 A1 PE20010349 A1 PE 20010349A1 PE 2000000707 A PE2000000707 A PE 2000000707A PE 0007072000 A PE0007072000 A PE 0007072000A PE 20010349 A1 PE20010349 A1 PE 20010349A1
Authority
PE
Peru
Prior art keywords
alkyl
phenyl
triazole
benzyl
compounds
Prior art date
Application number
PE2000000707A
Other languages
English (en)
Inventor
Bernd Buettelmann
Alexander Alanine
Emmanuel Pinard
Neidhart Marie-Paule Heitz
Georg Jaeschke
Rene Wyler
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20010349A1 publication Critical patent/PE20010349A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE TRIAZOL E IMIDAZOL DE FORMULA I DONDE R1-R4 ES H, CF3, OCF3, OCHF2, ALQUILO, ALCOXILO, HALOGENO, HIDROXILO, FENILO, BENCILO, AMINO, NITRO, PIRROL-1-ILO, ALQUIL-SULFONILO, ENTRE OTROS; R2 Y R3 SON -O-(CH2)2-O-, -O-CH2-O-, -O-(CH2)2-, ENTRE OTROS; X ES -N=, -N(R8)-, -CH=; Y ES -N=, =N-, N(R8), -CH=, UNO DE X O Y ES N; R5 ES -CH2-NR6R7; R6 Y R7 SON H, ALQUILO, C(O)-ALQUILO, HIDROXI-ALQUILO, ALQUENILO, COCH2OH; R6 Y R7 JUNTO A N SON -(CH2)2-O-(CH2)2, -CH2-CH[OC(O)CH3]-(CH2)2, ENTRE OTROS; R8 ES H, ALQUILO, ALQUENILO, ALQUINILO, (CH2)m-O-ALQUILO, (CH2)m-OH, ENTRE OTROS; m ES 0-4. SON COMPUESTOS PREFERIDOS {3-[5-(4-DIFLUOROMETOXI-FENIL)-1H-[1,2,4]TRIAZOL-3-IL]-BENCIL}-DIMETIL-AMINO (MEZCLA DE TAUTOMEROS), {3-[5-(4-FLUOROMETOXI-FENIL)-1H-[1,2,4]TRIAZOL-3-IL]-BENCIL}-DIMETIL-AMINA (MEZCLA DE TAUTOMEROS), 5-(4-DIFLUOROMETOXI-FENIL)-3-(3-PIRROLIDIN-3-ILMETIL-FENIL)-1H-[1,2,4]TRIAZOL (MEZCLA DE TAUTOMEROS), ENTRE OTROS. SE REFIERE TAMBIEN A UN PROCEDIMIENTO PARA LA PREPARACION. LOS COMPUESTOS I SON BLOQUEADORES SELECTIVOS DEL RECEPTOR NMDA POR LO QUE PUEDEN SER UTILES EN EL TRATAMIENTO DE ENFERMEDADES DE ALZHEIMER, PARKINSON, HUNTINGTON
PE2000000707A 1999-07-21 2000-07-17 Derivados de triazol e imidazol PE20010349A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99114313 1999-07-21

Publications (1)

Publication Number Publication Date
PE20010349A1 true PE20010349A1 (es) 2001-03-26

Family

ID=8238635

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000000707A PE20010349A1 (es) 1999-07-21 2000-07-17 Derivados de triazol e imidazol

Country Status (29)

Country Link
US (1) US6265426B1 (es)
EP (1) EP1070708B1 (es)
JP (1) JP3628946B2 (es)
KR (1) KR100383776B1 (es)
CN (1) CN1148357C (es)
AR (1) AR024790A1 (es)
AT (1) ATE257827T1 (es)
AU (1) AU773463B2 (es)
BR (1) BR0003075A (es)
CA (1) CA2314009C (es)
CO (1) CO5190713A1 (es)
DE (1) DE60007697T2 (es)
DK (1) DK1070708T3 (es)
ES (1) ES2211420T3 (es)
HR (1) HRP20000482A2 (es)
HU (1) HUP0002792A3 (es)
ID (1) ID26599A (es)
IL (1) IL137328A0 (es)
MA (1) MA26747A1 (es)
MX (1) MXPA00007069A (es)
NO (1) NO20003723L (es)
NZ (1) NZ505766A (es)
PE (1) PE20010349A1 (es)
PL (1) PL341616A1 (es)
PT (1) PT1070708E (es)
SG (1) SG98422A1 (es)
TR (1) TR200002097A3 (es)
UY (1) UY26253A1 (es)
ZA (1) ZA200003680B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962490A (en) * 1987-09-25 1999-10-05 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US6610723B2 (en) 2001-01-29 2003-08-26 Hoffmann-La Roche Inc. Imidazole derivatives
US7375136B2 (en) 2001-03-08 2008-05-20 Emory University pH-dependent NMDA receptor antagonists
US6951875B2 (en) * 2001-10-29 2005-10-04 Hoffmann-La Roche Inc. Conjugated aromatic compounds with a pyridine substituent
US7005432B2 (en) * 2002-05-16 2006-02-28 Hoffman-La Roche Inc. Substituted imidazol-pyridazine derivatives
CA2488117A1 (en) 2002-06-17 2003-12-24 Merck & Co., Inc. 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)pyrrolidine-3-carboxylates as edg receptor agonists
US20060004088A1 (en) * 2002-10-22 2006-01-05 Oct Inc. Furan derivatives for preventing and curing osteoporosis and pharmaceutical compositions containing the same
US7084145B2 (en) * 2002-10-25 2006-08-01 Pfizer Inc. Triazole compounds useful in therapy
CN1747936A (zh) * 2003-02-12 2006-03-15 特兰斯泰克制药公司 作为治疗试剂的取代吡咯衍生物
GB0303503D0 (en) * 2003-02-14 2003-03-19 Novartis Ag Organic compounds
GB0315111D0 (en) 2003-06-27 2003-07-30 Cancer Rec Tech Ltd Substituted 5-membered ring compounds and their use
DE602004027301D1 (de) * 2003-12-22 2010-07-01 Merck Sharp & Dohme Alpha-hydroxyamide als bradykininantagonisten oder inverse agonisten
NZ548208A (en) * 2004-02-12 2010-09-30 Transtech Pharma Inc Substituted azole derivatives, compositions, and methods of use
CN101374835B (zh) * 2006-01-30 2012-04-25 转化技术制药公司 作为PTPase抑制剂的取代的咪唑衍生物、组合物和使用方法
JO3019B1 (ar) * 2006-04-19 2016-09-05 Janssen Pharmaceutica Nv ثلاثي مستبدل 4،2،1-ثلاثي زولات
EP2118077B1 (en) 2007-02-08 2014-12-24 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
EP2529623A3 (en) * 2007-04-03 2013-03-13 E. I. du Pont de Nemours and Company Substituted benzene fungicides
US20110158907A1 (en) * 2007-04-19 2011-06-30 The Trustees Of The Univeristy Of Pennsylvania Diphenyl-heteroaryl derivatives and their use for binding and imaging amyloid plaques
US8420680B2 (en) * 2007-06-29 2013-04-16 Emory University NMDA receptor antagonists for neuroprotection
JO2784B1 (en) 2007-10-18 2014-03-15 شركة جانسين فارماسوتيكا ان. في 5,3,1 - Triazole substitute derivative
RU2474579C2 (ru) 2007-10-18 2013-02-10 Янссен Фармацевтика Нв Тризамещенные 1,2,4-триазолы
AU2009226988B2 (en) 2008-03-19 2013-05-23 Janssen Pharmaceutica Nv Trisubstituted 1, 2, 4 -triazoles as nicotinic acetylcholine receptor modulators
WO2009118187A1 (en) * 2008-03-27 2009-10-01 Evotec Neurosciences Gmbh Methods for treating disorders using nmda nr2b-subtype selective antagonist
JP5486591B2 (ja) 2008-05-09 2014-05-07 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ アセチルコリン受容体モジュレーターとしての三置換ピラゾール
RU2532394C1 (ru) * 2013-10-29 2014-11-10 Общество с ограниченной ответственностью "Научно-производственное объединение "Фарматрон" (НПО "Фарматрон") ПРИМЕНЕНИЕ БРОМИДА 1-β-ФЕНИЛЭТИЛ)-4-АМИНО-1,2,4-ТРИАЗОЛИЯ (ГИПЕРТРИЛ) КАК АКТИВНОЙ ОСНОВЫ ЛЕКАРСТВЕННЫХ СРЕДСТВ ДЛЯ КОРРЕКЦИИ НАРУШЕНИЙ ФУНКЦИОНИРОВАНИЯ НИТРОКСИДЕРГИЧЕСКОЙ СИСТЕМЫ ОРГАНОВ-МИШЕНЕЙ ПРИ ГОМОЦИСТЕИНЕМИИ И ОСТРЫХ НАРУШЕНИЯХ МОЗГОВОГО КРОВООБРАЩЕНИЯ
BR112017003918B1 (pt) 2014-08-29 2022-05-03 Fmc Corporation Composto, composições e mistura herbicida e método para o controle do crescimento da vegetação
KR102512548B1 (ko) 2017-12-22 2023-03-22 삼성디스플레이 주식회사 유기 전계 발광 소자 및 유기 전계 발광 소자용 함질소 화합물
US11912670B1 (en) 2023-10-25 2024-02-27 King Faisal University Ethyl 4-(5-(3-fluorophenyl)-4-phenyl-4H-1,2,4-triazol-3-ylthio)butanoate as an antimicrobial compound

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1579352A (en) * 1977-05-06 1980-11-19 Lepetit Spa 3,5-disubstituted-1h-1,2,4-triazoles
DE19643037A1 (de) * 1996-10-18 1998-04-23 Boehringer Ingelheim Kg Neue Oxadiazole, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel
AU744297B2 (en) * 1997-07-03 2002-02-21 Neurogen Corporation Certain diarylimidazole derivatives; a new class of NPY specific ligands
DE19816880A1 (de) * 1998-04-17 1999-10-21 Boehringer Ingelheim Pharma Neue Diphenyl-substituierte 5-Ring-Heterocyclen, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel
US7487474B2 (en) 2003-01-02 2009-02-03 Pdf Solutions, Inc. Designing an integrated circuit to improve yield using a variant design element

Also Published As

Publication number Publication date
UY26253A1 (es) 2000-10-31
NO20003723L (no) 2001-01-22
TR200002097A2 (tr) 2001-02-21
ES2211420T3 (es) 2004-07-16
AU773463B2 (en) 2004-05-27
JP2001064263A (ja) 2001-03-13
CN1148357C (zh) 2004-05-05
ZA200003680B (en) 2001-01-22
CA2314009A1 (en) 2001-01-21
AU4865100A (en) 2001-01-25
EP1070708B1 (en) 2004-01-14
TR200002097A3 (tr) 2001-02-21
NZ505766A (en) 2002-03-28
KR100383776B1 (ko) 2003-05-12
PT1070708E (pt) 2004-05-31
NO20003723D0 (no) 2000-07-20
ID26599A (id) 2001-01-25
DK1070708T3 (da) 2004-05-10
KR20010049825A (ko) 2001-06-15
AR024790A1 (es) 2002-10-23
BR0003075A (pt) 2001-03-13
CN1281852A (zh) 2001-01-31
ATE257827T1 (de) 2004-01-15
SG98422A1 (en) 2003-09-19
HUP0002792A2 (hu) 2001-09-28
MA26747A1 (fr) 2004-12-20
US6265426B1 (en) 2001-07-24
IL137328A0 (en) 2001-07-24
DE60007697T2 (de) 2004-12-09
DE60007697D1 (de) 2004-02-19
EP1070708A1 (en) 2001-01-24
MXPA00007069A (es) 2002-04-24
HU0002792D0 (en) 2000-09-28
PL341616A1 (en) 2001-01-29
JP3628946B2 (ja) 2005-03-16
CA2314009C (en) 2008-09-30
CO5190713A1 (es) 2002-08-29
HUP0002792A3 (en) 2002-10-28
HRP20000482A2 (en) 2001-06-30

Similar Documents

Publication Publication Date Title
PE20010349A1 (es) Derivados de triazol e imidazol
US20190144398A1 (en) Method for treating inflammatory disorders
AU2007267843B2 (en) Method for treating proliferative disorders associated with protooncogene products
PE20060525A1 (es) Compuestos heterociclicos como inhibidores de cetp
US20110046125A1 (en) Method for treating infections
MXPA05001807A (es) Nuevos derivados de aminoindazol utilizados como medicamentos y composiciones farmaceuticas que los contienen.
DK1437349T3 (da) Substituerede isoxazoler og anvendelse deraf som antibiotika
CO4970829A1 (es) Polimorfo antifungico cristalino
PE20081704A1 (es) Derivados de azacicloalcanos como inhibidores de estearoil-coenzima a delta-9 desaturasa
KR970704738A (ko) 항-헬리코박터제인 아졸론의 우레아 및 티오우레아 유도체(Anti-helicobacter urea and thiourea derivatives of azolones)
PE20010068A1 (es) Compuestos derivados de piperidina como inhibidores de renina
HUP0103921A2 (hu) [1,2,4]triazolo[1,5-c]pirimidin-származékok és ezeket tartalmazó gyógyszerkészítmények
DE2967005D1 (en) 2-alkoxycarbonylamino benzimidazoles having a halogen-containing substituent, their preparation and their use as parasiticides
CN112654349A (zh) PIKfyve抑制剂
ES2899868T3 (es) Tratamientos de combinación que comprenden la administración de 1H-pirazolo[4,3-b]piridinas
PE20050950A1 (es) Derivados de triazol sustituidos como antagonistas de oxitocina
RU2332996C2 (ru) Производные гидразонпиразола и их применение в качестве лекарственного средства
CA2479363A1 (en) Thiopyrimidine and isothiazolopyrimidine kinase inhibitors
JP2004508366A5 (es)
NO20045001L (no) Fremgangsmate for fremstilling av 5-[[2(R)-[1(R)-[3,5-bis(trifluormetyl)fenyl]etoksy]-3(S)-(4-fluorfenyl)-4-morfolinyl]metyl]-1,2-dihydro-3H-1,2,4-triazol-3-on
PE20070591A1 (es) Derivados de 6-heteroarilpiridoindolona y su preparacion
NZ334701A (en) Dihydropyrones and use in treating retrovirus infections and diseases
CA2494345A1 (en) Combination of an aromatase inhibitor with a bisphosphonate
MXPA02011464A (es) Derivados 1,4-diazepan-2,5-diona y su uso como antagonistas del receptor de la nk-1.
GB9610031D0 (en) Chemical compounds

Legal Events

Date Code Title Description
FD Application declared void or lapsed